Stavudine (d4T), a nucleoside reverse transcriptase inhibitor (NRTI), remains widely used in first-line antiretroviral treatment (associated with a second NRTI, generally lamivudine, and a non-nucleoside reverse transcriptase inhibitor, either nevirapine or efavirenz) of HIV-infected patients living in low-or middle-income countries because of its availability as generic, low-cost, easy to use, fixed-dose combinations with lamivudine alone or with lamivudine and nevirapine [1] . Initially, the recommended twice-daily dose of d4T was 40 mg in patients weighing >60 kg and 30 mg in those weighing <60 kg. Because of the serious adverse effects associated with d4T, including lipoatrophy [2], the World Health Organization (WHO) recommended, in 2007, to lower the dosage to 30 mg twice daily for all patients, irrespective of their body weight [3, 4] . The efficacy of treatment has been shown to be maintained with this lower dosage [5] . Safety seems to be slightly improved, as suggested by several studies, with respect to mitochondrial toxicity and body composition [6] [7] [8] ; however, the clinical effect remains unclear. WHO and other experts now encourage programme leaders to switch to less toxic first-line NRTI backbones, including either zidovudine (AZT) or tenofovir disoproxil fumarate, but d4T will remain in use until full application of WHO recommendations [9, 10] . In order to assess the effect of lower d4T dosage on lipoatrophy, we compared the prevalence of lipoatrophy in urban Cameroon between patients on d4T-related treatment who had received exclusively the d4T 30 mg dosage and those who received both d4T 40 mg and d4T 30 mg since treatment initiation. These two groups were also compared with patients on AZT-related treatment.
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Introduction

Methods
Setting and patient population
A cross-sectional study was conducted in the HIV/AIDS outpatient clinic of the Central Hospital in Yaoundé, Cameroon from March to May 2008. The protocol of the study was approved by the National Ethics Committee of Cameroon. All patients provided written informed consent. Inclusion criteria were >18 years of age and treatment with d4T-or AZT-based antiretroviral therapy for >6 months. Exclusion criteria were any switch of d4T or AZT during the whole treatment period, exclusive use of the 40 mg dosage among patients receiving d4T, pregnancy, HIV wasting syndrome and any major body modification unrelated to lipodystrophy. Symptomatic patients were eligible, with the exception of those who met one of the latter two exclusion criteria.
Clinical assessment, treatment group classification and lipodystrophy definition
Sociodemographic information was collected by interview. Details on drug treatment history were obtained from medical and pharmaceutical files of the hospital. The choice of d4T or AZT in first-line treatment was at the physicians' discretion. Patients undergoing a d4T-based regimen received the 40 mg dosage if they weighed ≥60 kg and the 30 mg dosage if they weighed <60 kg prior to publication of the 2007 WHO recommendations, and, thereafter, the 30 mg dosage regardless of their body weight (for both treatment-naive as well as previously treated patients) [4] .
Patients on d4T-related therapy who received exclusively the 30 mg dosage were assigned to the d4T 30 group. Those who were prescribed the 40 mg dosage at least once were assigned to the d4T 30/40 group, regardless of their duration on the 40 mg dosage. Finally, patients on AZT-related treatment were assigned to the AZT group.
A specific enquiry form was filled out by a trained interviewer to evaluate lipodystrophy according to body changes reported by the patient [11] . Accumulation or loss of fat was reported for eight body sites (face, neck, dorsocervical spine, breast, abdomen, buttocks, arms and legs). For each site, change was graded into 'none', 'mild', 'moderate' or 'severe' for fat losses and accumulations separately. Lipoatrophy was defined as ≥1 report of fat loss at any body site. Lipohypertrophy was defined as ≥1 report of fat accumulation at any site, excluding isolated abdominal fat accumulation. Patients reporting both lipoatrophy and lipohypertrophy were defined as having mixed syndrome. A lipodystrophic patient (that is, a patient with lipoatrophy, lipohypertrophy or both) can be classified as having isolated lipoatrophy, isolated lipohypertrophy or a mixed syndrome. In the present work, lipoatrophy refers to both isolated lipoatrophy and mixed syndrome unless specified. Two definitions were considered that were dependent upon the severity of the changes reported by the patient: a 'strict' definition based on ≥1 body site with moderate to severe changes and a 'large' definition based on ≥1 body site with mild to severe changes.
Statistical analyses
Quantitative variables were compared between treatment groups (d4T 30 , d4T 30/40 and AZT) using MannWhitney U non-parametric tests or Student's t-tests, whereas χ 2 tests were used for qualitative variables. Prevalences of lipodystrophy (any type), lipohypertrophy, lipoatrophy and mixed syndrome were compared between groups using χ 2 tests (or Fisher's exact tests when appropriate). Bivariate analyses based on logistic regressions were used to assess the association between the risk of lipoatrophy and the following covariates: treatment group, age, gender, CD4 + T-cell count at treatment initiation and treatment duration (both as a continuous or a categorical variable). All these covariates were then included in a multiple logistic regression. Multivariate analyses were run both for the 'strict' and 'large' definitions of lipoatrophy, and interactions between treatment group and the other covariates were tested. Because of non-normality of distributions, medians with interquartile ranges (IQRs) have been provided for several quantitative variables (duration since HIV diagnosis, treatment duration and CD4 + T-cell count). All statistical analyses were performed using the SAS package version 9.2 (SAS Institute, Inc., Cary, NC, USA). Differences were considered significant for P<0.05.
Results
Among 249 patients included in the study, 5 were subsequently excluded from the analyses because they had incomplete data on antiretroviral treatment and 1 because he had received only d4T 40 mg. Of the remaining 243 patients, 69 had received d4T 30 mg, 64 had received d4T 30 and 40 mg, and 110 had received AZT (in association with lamivudine and efavirenz or nevirapine in all groups). The three groups were similar in terms of their age and gender distribution (Table 1) . By contrast, body weight was lower in the d4T 30 group and duration since HIV diagnosis was longer in the d4T 30/40 group. The median duration of treatment was similar between the d4T 30 The overall prevalence of lipodystrophy according to the 'large' definition was 60% (Table 1) , with a significant difference between sexes (45.6% for males and 64.5% for females; P=0.01). The sex-related difference was also found with the 'strict' definition (7.0% for males and 21.5% for females; P=0.01). The higher prevalence of lipodystrophy in females was mostly the result of a higher frequency of lipohypertrophy (19.3% in males and 41.4% in females; P=0.002 for the 'large' definition and 3.5% in males and 14.0% in females; P=0.03 for the 'strict' definition), whereas frequency of lipoatrophy was similar (26.3% in males and 23.6% in females; P=0.62 for the 'large' definition and 3.5% in males and 7.5% in females; P=0.29 for the 'strict' definition). The prevalences of lipodystrophy were highest in the d4T 30/40 group and lowest in the AZT group, regardless of the definition considered. By contrast, the highest prevalences of isolated lipohypertrophy were observed in the d4T 30 group. When considering isolated lipoatrophy, the prevalences were very low in the d4T 30 group and, to a lesser extent, in the AZT group compared to d4T 30/40 group. Finally, the overall prevalence of lipoatrophy (combining isolated lipoatrophy and mixed syndrome) was comparable between the d4T 30 group and the AZT group, but was higher in the d4T 30/40 group (Table 1) .
In the bivariate analyses, only the treatment group was significantly associated with the risk of lipoatrophy. After adjustment for gender, age, treatment duration and CD4 + T-cell count at treatment onset ( 28 (11) 11 (16) 9 (14) 0.76 8 (7) 0.07 Isolated lipoatrophy 'Large' definition, n (%) 22 (9) 1 (1) 14 (22) 0.0001 (15) 13 ( 
Discussion
The overall prevalence of lipoatrophy found in the present study (7-24% depending on the definition) was in the range of previous values reported in African settings [12] [13] [14] [15] . Importantly, patients who were treated with d4T 30 mg since treatment initiation had less lipoatrophy than those who had received the 40 mg dosage and had subsequently switched to the 30 mg dosage in agreement with WHO recommendations. Moreover, the prevalence of lipoatrophy did not differ between the d4T 30 and the AZT groups.
These results suggest that a dose reduction of d4T at the onset of the treatment could have a beneficial effect in reducing the risk of lipoatrophy. It also suggests that this fat-loss syndrome is not reversible, or at least can only be reversed slowly. Indeed, patients in the d4T 30/40 group had all switched to 30 mg ≥6 months prior to the study, but their prevalence of lipoatrophy remained at least twofold higher as compared with the d4T 30 group. Several randomized controlled studies investigated the effect of reducing the d4T dose on body composition and lipid metabolism [6] [7] [8] . None of these studies reported significant improvement in body fat distribution. Treatment switch studies from d4T to other NRTIs also indicate that fat recovery is a slow process [16] [17] [18] [19] .
Our study is original in that it includes a group of patients who received a reduced dosage of d4T since treatment initiation. By comparison, previous studies that investigated the effect of a d4T dose reduction have evaluated change in body composition after a reduction of the drug dose. Thus, lipoatrophy might have occurred when the patients received the higher dosage.
Our estimates of prevalence should be seen as a minimum, especially in the d4T groups, because of the cross-sectional design and the exclusion of patients who had switched from d4T prior to the study (possibly because of lipoatrophy). Mean treatment duration was higher in the d4T 30/40 group compared with the d4T 30 and AZT groups. This difference in duration on highly active antiretroviral therapy could partially explain the difference in prevalence of lipoatrophy, as treatment duration is known to be associated with the risk of lipodystrophy development [14, 20, 21] . To account for a potential effect of treatment duration, we included the duration variable in the models. We also conducted subanalyses on a sample of patients with treatment duration >12 months in order to homogenize the duration between groups, and found similar results. In addition to treatment duration, the two d4T Table 2 . Association between antiretroviral treatment and lipoatrophy with adjustment for gender, age, treatment duration and CD4 + T-cell count at treatment onset Total n=239. 'Large' and 'strict' definitions denote mild to severe lipoatrophy and moderate to severe lipoatrophy, respectively. a CD4 + T-cell count at treatment onset. AZT, zidovudine; CI, confidence interval; d4T, stavudine; HAART, highly active antiretroviral therapy.
groups were also probably different in terms of weight and corpulence at treatment initiation, as prior to the revised WHO guidelines, the use of 30 mg was recommended for patients with body weight <60 kg. This difference could have had an effect on the development of lipoatrophy. Finally, it should be acknowledged that potential selection biases could not be investigated, as information regarding the number and characteristics of patients excluded was not available.
In conclusion, the present findings suggest that the use of d4T at a lower dosage might increase safety with regard to its effect on lipid metabolism and changes in body fat distribution. This argues for the possible use of d4T as an alternative treatment in the event of unavailability, resistance or intolerance (for example, anaemia or renal disorders) to less toxic NRTIs (AZT or tenofovir disoproxil fumarate).
